GlassScriptPhysician profile
Ann K Begert
NPI 1538265103
$1,379.91
in general payments reported to CMS, 2019-2025
23 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2022: $200 · 2023: $403 · 2024: $276 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,007.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $234.44 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $184.38 | 2019-2024 | Repatha |
| Lilly USA, LLC | $175.70 | 2022-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.68 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $102.84 | 2022-2024 | Farxiga, Airsupra |
| Abbvie INC. | $54.67 | 2022-2023 | Creon, Linzess |
| Edwards Lifesciences Corporation | $47.12 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Janssen Pharmaceuticals, INC | $46.46 | 2022-2024 | Xarelto |
| Pfizer INC. | $42.11 | 2025 | |
| Viatris Specialty LLC | $35.45 | 2025 | Yupelri |
| Glaxosmithkline, LLC. | $34.91 | 2024-2025 | Shingrix, Arexvy, Nucala |
| Abbott Laboratories | $29.14 | 2025 | Freestyle Libre 3 |
| Supernus Pharmaceuticals, INC. | $28.66 | 2025 | Qelbree |
| Sage Therapeutics, LLC | $28.66 | 2025 | Zurzuvae |
| Biohaven Pharmaceutical Holding Company LTD. | $23.19 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $22.97 | 2023 | Watchman |
| Neurelis, INC. | $22.95 | 2023 | Valtoco |
| Gilead Sciences, INC. | $22.04 | 2025 | |
| Horizon Therapeutics Plc | $22.02 | 2019 | |
| Axsome Therapeutics, INC. | $19.67 | 2023 | Sunosi |
| Teva Pharmaceuticals USA, INC. | $18.99 | 2023 | Airduo Digihaler |
| Bayer Healthcare Pharmaceuticals INC. | $11.75 | 2022 | |
| Linus Health, INC. | $10.11 | 2024 | Core Cognitive Evaluation |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Begert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.